In addition, the pharmacogenomic study of the DEPs in GSCA also showed that the downregulation of proteins such as PRDX4, GDI1, and YWHAE and the upregulation of proteins such as CLEC3B, KRT38, KRT37, and HNRNPCL1 were linked to higher sensitivity toward 30 pan-cancer CTRP drugs. This evidence concerns the gene PRDX4 and cancer.